Organization (Industry)
Great Lakes NeuroTechnologies (United States)
ClinicalTrials.gov lists Great Lakes NeuroTechnologies (United States) as lead sponsor of 19 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Great Lakes NeuroTechnologies (United States): 19 lead-sponsored trials and 1 legal-entity registration.
Disease areas (9)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Parkinson Disease | 15 |
| Tremor | 8 |
| Hypokinesia | 7 |
| Essential Tremor | 3 |
| Cerebral Palsy | 1 |
Showing 5 of 9 disease areas.
Trials by start year as sponsor or collaborator (10)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2019 | 2 |
| 2018 | 1 |
| 2016 | 1 |
| 2015 | 1 |
| 2014 | 5 |
| 2013 | 3 |
| 2012 | 2 |
| 2011 | 3 |
| 2008 | 1 |
Recruitment duration, a model prediction: none of the 19 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 0 of 2 hit target (n=2) | 0 of 2 on time (n=2) |
Journals published in (6)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Anesthesiology | 2 |
| American journal of respiratory and critical care medicine | 1 |
| Anesthesia and analgesia | 1 |
| Journal of Parkinson's disease | 1 |
| Mayo Clinic proceedings | 1 |
Showing 5 of 6 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 67 | 24 | 2025-12-23 |
Financing and grant events (4)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-08-21 | SBIR award | 1,134,607 | Reporter |
| 2023-09-26 | SBIR award | 289,515 | Reporter |
| 2021-06-25 | SBIR award | 802,719 | Reporter |
| 2020-07-01 | SBIR award | 696,634 | Reporter |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 3 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| GREAT LAKES NEUROTECHNOLOGIES INC. | Cleveland, US | FDA |
Organization relationships (10)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 10 |
| University of Rochester | Co sponsors trial with | 4 |
| The Cleveland Clinic | Co sponsors trial with | 3 |
| Rush University Medical Center | Co sponsors trial with | 3 |
| Harris Health System | Co sponsors trial with | 2 |
Showing 5 of 10 relationships.
Latest dated events (94)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-03-12 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-12-23 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-09-09 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-08-21 | SBIR award | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-08-05 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 94 events.
Biomarker capability evidence (6)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| EEF1A2 | Trial sponsor | Named in trial inclusion criteria |
| EEF1A2 | Trial sponsor | Named in trial inclusion criteria |
| VIM | Trial sponsor | Named in trial exclusion criteria |
| EEF1A2 | Trial sponsor | Mentioned in trial text |
| EEF1A2 | Trial sponsor | Mentioned in trial text |
Showing 5 of 6 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, sec-reported annual financials, fda warning letters, fda untitled letters, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.